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Aims: To investigate the possible effects of the Food andDrug Administration (FDA) Public Health Notifications in 2008
and 2011 regarding surgical trends in transvaginal mesh (TVM) placement for stress urinary incontinence (SUI) and
related mesh revision surgery in Female Pelvic Medicine & Reconstructive Surgery (FPMRS) practice in tertiary care
academic medical centers in the United States. Methods: Surgical volume for procedures performed primarily by
FPMRS surgeons at eight academic institutions across theUSwas collected usingCurrent Procedural Terminology (CPT)
codes for stress urinary incontinence repair and revision surgeries from2007 to 2013. SAS statistical softwarewas used to
assess for trends in the data.Results: There was a decrease in the use of syntheticmesh sling for the treatment of SUI at
academic tertiary care centers over the past 7 years; however, this was not statistically significant. While the total
number of surgical interventions for SUI remained stable, there was an increase in the utilization of autologous fascia
pubovaginal slings (AFPVS). The number ofmesh sling revision surgeries, including urethrolysis and removal or revision
of slings, increased almost three-fold at these centers. Conclusions: These observed trends suggest a possible effect of
the FDA Public Health Notifications regarding TVM on surgical practice for SUI in academic centers, even though they
did not specifically warn against the use of synthetic mesh for this indication. Indications for surgery, complications, and
outcomes were not evaluated during this retrospective study. However, such data may provide alternative insights into
reasons for the observed trends. Neurourol. Urodynam. 36:1155–1160, 2017. # 2016 Wiley Periodicals, Inc.
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INTRODUCTION
Synthetic midurethral mesh slings have become the gold
standard in surgical repair of stress urinary incontinence (SUI)
in the field of Female Pelvic Medicine and Reconstructive
Surgery (FPMRS), replacing needle suspension and Burch
colposuspension as the most popular procedure for SUI.1–3
However, there is increasing controversy surrounding the use
of transvaginal mesh (TVM) to treat SUI and pelvic organ
prolapse (POP). Synthetic mesh for use in SUI repair was first
approved in 1998 by the Food and Drug Administration (FDA)
via 510(k) Premarket Notification after finding it substantially
equivalent to surgical mesh for hernia repair.4 In October of
2008, the FDA issued a Public Health Notification and Safety
Communication due to concern over increased reporting
through the Manufacturer and User Device Experience
(MAUDE) database of complications associated with transvagi-
nal placement of surgical mesh (TVM) to treat SUI and POP.5
This was followed in July of 2011 with an updated Safety
Communication released by the FDA on the safety and efficacy
of TVM for POP.6 Of note, this second July 2011 Public Health
Notification did not comment specifically on the safety of using
mesh for the treatment of SUI. Complications associated with
midurethralmesh sling repair of SUI include pain, dyspareunia,
mesh erosion and exposure.7
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Interestingly, Rice et al. found that there has been an increase
in patient perceived mesh complications since the 2011 Public
Health Notification, but that the actual frequency, type, and
location of mesh complications has not changed.8 Patient
perceptions of vaginal mesh have been affected by a variety of
factors in recent years, including advertisements for recruit-
ment of plaintiffs for mesh litigation.9 Nevertheless, the effect
of the FDA Safety Communications on surgical practice for SUI
remains unclear. We recently showed that there has been a
significant change in POP surgery in this practice setting over
the last seven years, with a substantial reduction in transvagi-
nal mesh augmented repair of POP as well as a simultaneous
increase in the number of mesh revision surgeries.10 The
objective of this study is to evaluate for changes in trends in SUI
surgery, including sling revisions for mesh-related complica-
tions among FPMRS specialists over the last 7 years at tertiary
care medical centers across the United States.
MATERIALS AND METHODS
Surgical volume of procedures performed by FPMRS
specialists at eight academic institutions was collected using
CPT codes for SUI sling procedures (57288), urethrolysis
(53500), transvaginal sling incision (57287), and autologous
fascia procedures (20920, 20922, 20926) (Appendix 1). The
study was approved by the Medical University of South
Carolina institutional review board and was inclusive of all
participating academic institutions. Only case volume infor-
mation was exchanged between participating centers and all
patient information was de-identified.
The eight tertiary referral centers participating in this
study were: Medical University of South Carolina, Charles-
ton, SC; University of Michigan Health Science Center, Ann
Arbor, MI; Virginia Mason Medical Center, Seattle, WA; New
York University Langone Medical Center, New York, NY;
University of Texas Southwestern Medical Center, Dallas, TX;
Vanderbilt University Medical Center, Nashville, TN; Lahey
Hospital & Medical Center, Burlington, MA; Keck Medicine of
University of Southern California, Los Angeles, CA. These
were chosen in order to represent a broad geographic range
across the US and each section of the American Urologic
Association. Each institution involved had at least one senior
surgeon that was Board Certified in Urology, a member of
Society of Urodynamics, Female Urology and Urogenital
Reconstruction (SUFU), considered a specialist at their
institution for Female Pelvic Medicine, and is presently
board-certified in FPMRS (though that Board was not
available during the entire time period that encompassed
the CPT billing data collection).
The first FDA Public Health Notification addressing trans-
vaginal mesh complications was released October 2008 with
an updated statement in July 2011. To allow for a margin of
over 1.5 years of practice stability prior to and after the
notifications, a time period of January 1, 2007 to December 31,
2013 was selected to investigate the potential effect of the
notifications on SUI surgical practice. A total of 7,739 surgical
procedures related to SUI across the eight institutions during
the study period were identified. These included both
synthetic and fascial sling interventions, as well as sling
revision surgeries. Two centers (University of Michigan
Health Science Center and Virginia Mason Medical Center)
were partially excluded from the analysis except for the
evaluation of trend in urethral revision surgery due to
variations in coding practice, in that we could not distinguish
synthetic midurethral sling from autologous fascia pubova-
ginal sling (AFPVS) because they only used code 57288 and
did not include separate CPT codes for graft harvesting. After
exclusion of these cases, 4,788 surgical procedures were
included across the eight institutions. The total number of
mesh slings was calculated by subtracting the instances of
CPT codes for autologous fascia grafts (20920, 29022, 20926)
from the total number of instances of the CPT code for sling
operation for stress incontinence (57288). The number of
mesh revision surgeries was calculated by adding together
the instances of CPT codes for urethrolysis (53500) and
removal or revision of sling for stress incontinence (57287).
Statistical analysis was performed using SAS statistical
software. The observed trends were assessed by determining
Spearman correlation coefficients and performing Pearson’s
chi-squared tests when appropriate. Significance of trend was
defined by P-value <0.05. The data was also stratified by
academic center and analyzed with the aforementioned
methods in order to assess for potential weighted bias or
center effect.
RESULTS
This multi-institutional collaborative study included a total
of 4,788 interventions for SUI performed between January 1,
2007 and December 31, 2013. During the 7 years evaluated, a
decrease in the use of synthetic mesh to treat SUI was noted
(Fig. 1); however, this was not statistically significant
(P¼ 0.25). Of note, two centers (New York University Langone
Medical Center and Vanderbilt University Medical Center) did
have a statistically significant decrease in the utilization of
mesh for SUI during this time (P¼ 0.036 and P¼ 0.016,
respectively). One center (Lahey Hospital & Medical Center)
had an overall increase in mesh implantation during this time
period that was not statistically significant (P¼0.76). A
subanalysis of the data looking at dates from 2011 to 2013
was done to evaluate for the possibility of an independent
effect of the second FDA Public Health Notification from
July 2011 on practice patterns. In this subanalysis, there was
a significant decrease observed in use of synthetic mesh from
2011 to 2013. However, when this subanalysis was stratified
by center, it was found to be largely the effect of practice
patterns at Lahey Hospital & Medical Center, which had a
significant drop-off after a brief period of rapid increase from
2009 to 2010. The remaining centers did not have a significant
change utilization of mesh since 2011.
Surgical volume for treatment of SUI has remained relatively
stable over the past 7 years (Fig. 2); however, there has been a
significant increase in the utilization of AFPVS when compared
to total SUI intervention, from21%of all SUI surgeries in 2007 to
30% in 2013 (Fig. 3, P< 0.0001). Over this same time period, the
number of urethral revision surgeries (urethrolysis and sling
incision) increased by almost three-fold from145 in 2007 to 392
in 2013. (Fig. 4, P¼0.00045).
DISCUSSION
Current trends in surgical management of stress urinary
incontinence have not been well defined in this era of
increased scrutiny over procedures using synthetic vaginal
mesh. Several studies have investigated these trends for both
SUI and POP in the past. However, the majority of these
featured end-points that do not include the FDA Public Health
Notifications released in 2008 and 2011. As a part of the
Urologic Diseases of America Project, Anger et al. (2009)
randomly sampled Medicare data of female beneficiaries aged
greater than 65 years to investigate patterns in the surgical
treatment of women with SUI in the United States from 1992
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to 2001.2 They found a ‘‘drastic increase’’ in the numbers and
rates of sling placements for SUI from 1995 to 2001, gradually
replacing needle suspension as the most commonly per-
formed incontinence procedure. Rogo-Gupta et al. (2013)
continued this study by looking at Medicare data from 2002
to 2007.11 They reported a continued increase in sling
procedures performed each year. However, it is important
to note that the authors of both studies were unable to
differentiate between bladder neck fascial slings and mid-
urethral synthetic slings, because they share the same CPT
code (57288). It is likely that the majority of those procedures
were midurethral synthetic slings; however, in our study, we
were able to circumvent this potential limitation by
subtracting the instances of CPT codes for autologous fascia
harvest from the total instances of the CPT code 57288 to
determine the number of procedures utilizing synthetic slings
for most centers. Due to this methodology and depending on
center coding practice, some centers were excluded from our
data set which is a limitation of our study design. Another
limitation of the studies by Anger et al. and Rogo-Gupta et al.
is that Medicare patients over the age of 65 years reflect only
a subset of women who suffer from SUI. Funk Johnson et al.
published a similar study in 2012 looking at trends in SUI
surgery between 2000 and 2009; however, their focus was on
women between the ages of 18 and 64 years.3 They utilized
the Thomson Reuters MarketScan Commercial Claims and
Encounters database which contains healthcare claims data
from employer-based plans in the United States. The authors
noted increasing rates of sling procedures in this population
over the years studied, with the greatest increase being in the
group of women aged 35–50 years old when adjusted for age.
This study was also limited by the lack of differentiation
between bladder neck fascial slings and midurethral syn-
thetic slings.
Another finding of the study by Rogo-Gupta et al. was an
increasing trend in surgical management of SUI in ambulatory
surgery centers, with a simultaneous decline in inpatient
management.11 A 2012 study looking at trends in ambulatory
procedures for SUI by Suskind et al. found a four-fold increase in
midurethral sling procedures from 2001 to 2009.12 The authors
Fig. 2. Trend in surgical volume for stress urinary incontinence, not including revision surgery. CPT code 57288. FDA†—October 2008 Public Health
Notification and Safety Communication, FDA‡—July 2011 UPDATE to Public Health Notification and Safety Communication.
Fig. 1. Trend ofmesh implant surgery for treatment of stress urinary incontinence surgery. Calculated by subtracting the instances of CPT codes that signifyuse of
autologous fascia (20920, 29022, 20926) fromthe total numberof instances of theCPT code for sling operation for stress incontinence (57288). FDA†—October 2008
Public Health Notification and Safety Communication, FDA‡—July 2011 UPDATE to Public Health Notification and Safety Communication.
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believe that they were potentially able to mitigate the
limitation of lack of a specific CPT code to specify sling type
(fascia or synthetic) by utilizing the Florida State Ambulatory
Surgery Database. This database contains only ambulatory
procedures, which likely limits their study to synthetic slings.
Notably, they did not demonstrate a decline in implantation of
synthetic mesh for SUI in the year after the October 2008 FDA
Public Health Notification.
One strength of our study is that by choosing dates
between 2007 and 2013, it is inclusive of both of the FDA
Public Health Notifications5,6 with one full clinical year prior
to the initial Public Health Notification and two full years of
clinical data following the second one. Only one other study13
has attempted to evaluate changes in surgical practice for SUI
and POP in response to these notifications. The authors
compared the number of SUI and POP surgeries, including
revisions, in the 6 months before and after the 2011 Public
Health Notification using the State Ambulatory Surgery
Databases from California, South Carolina, Illinois, and
Maryland. These databases are limited to information about
practice patterns in ambulatory surgery centers. Our study is
complementary to this one in that it highlights the changes in
practice patterns at academic tertiary care centers. Other
strengths of our study include the large number of procedures
performed, the high volume academic surgeons, and the
cross-sectional sampling of tertiary care referral centers
across multiple geographic regions in the United States
inclusive of inpatient and outpatient surgeries.
Taking our results into consideration in conjunction with
the findings of Polland et al., the data appears to suggest that
the Food and Drug Administration Safety Communications of
2008 and 2011 may potentially have had an effect on the
management of stress urinary incontinence. Both studies
observed a decline in the utilization of synthetic mesh slings
for treatment of SUI in their respective settings, although
neither trend was statistically significant.13 While the total
Fig. 3. Trend in autologous fascia pubovaginal sling procedures for surgical treatment of stress urinary incontinence. Calculated as a ratio of CPT codes that
signify use of autologous fascia (20920, 29022, 20926) over the CPT code for stress incontinence (57288). FDA†—October 2008 Public Health Notification and
Safety Communication, FDA‡—July 2011 UPDATE to Public Health Notification and Safety Communication.
Fig. 4. Trend in mesh revision surgery: urethral intervention for sling. CPT codes for urethrolysis, transvaginal, secondary, open, including
cystourethroscopy (53500), and removal or revision of sling for stress incontinence (57287). FDA†—October 2008 Public Health Notification and Safety
Communication, FDA‡—July 2011 UPDATE to Public Health Notification and Safety Communication.
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number of surgical interventions for SUI has remained stable
over the study period, there has been a significant increase
in the utilization of AFPVS as a percentage of total SUI
intervention. In their 2015 abstract, Khan et al. independently
confirm this increase in utilization of AFPVS at New York
University Langone Medical Center.14 Similar to Polland et al.,
we found a significant increase in sling revision procedures
since the FDA Public Health Notifications (P<0.001 and
P¼0.00045, respectively). When we stratified the revision
data by center, three of the centers had a statistically
significant increase in revision surgeries, and three of them
had an increase in revision surgeries that was not statistically
significant. Two centers had a decrease in mesh revision
surgeries, one of which was statistically significant (Lahey
Hospital & Medical Center). However, the significance of this
trend is diminished by the fact that the number of revision
cases they perform annually is quite low, with a low of 10 in
2011 and a high of 16 in 2007. These observed trends could
also be related to changes in referral patterns, an increased
awareness and recognition of potential mesh complications,
an actual increase in mesh complications, or other factors.
This review is not necessarily representative of community
and non-tertiary center practice where autologous fascial
slings are much less commonly performed. The increased use
of AFPVS at these centers is likely due to a combination of
factors, not the least of which are the complexity of the
patients seen at tertiary centers and the bias seen by these
FPMRS tertiary care surgeons due to common evaluation and
treatment of mesh related complications.
Limitations of this study include potential regional
variations in practice patterns and coding practice as well
as bias of tertiary care facilities and associated referral
patterns. Fluctuations in the number of providers at each
center may have occurred over the course of the study,
although each center had at least one individual surgeon
throughout the entire study period. By exclusively investigat-
ing procedures performed at academic centers, we introduced
the possibility of bias via center effect, whereby one academic
center could skew the observed trends for the aggregate
multicenter data and limit the generalizability of the
observed trends. In an attempt to identify and minimize
this center effect, we also stratified and observed trends by
center. Due to the size of the multi-institutional study we
analyzed only case volume using CPT codes for procedures.
This method of data collection has limitations that include
the inability to identify what the indications for mesh
removal were. Additionally, the time-lapse between original
surgery and re-intervention is unknown. The CPT codes
themselves have certain limitations. For example, the code for
urethrolysis (53500) cannot differentiate midurethral slings
from bladder neck slings, nor can it clearly determine
whether the revision was done due to mesh or because a
fascial sling was too tight. Further studies that necessitate
approval from the Institutional Review Board can address
these issues. Despite these limitations, it is clear that FPMRS
practice patterns have changed over the last decade.
CONCLUSIONS
While the total surgical volume for SUI intervention has
remained stable over the last 7 years, it is evident that there is
increased use of AFPVS during this time period. During this
time period, there has been a concurrent increase in mesh sling
revision surgeries. These findings suggest a potential lasting
effect of the FDA Public Health Notifications on practice
patterns for treatment of SUI among tertiary care FPMRS
providers at academic medical centers, even though the Safety
Communications did not specifically warn against the use of
synthetic mesh for this indication or report on specific
complications for midurethral slings for SUI. This trend is
likely the result of multiple factors reflecting the complex
medico-legal and regulatory atmospheres as well as evolving
patient perceptions of TVM.
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APPENDIX 1
Common Procedural Technology (CPT) Codes Referenced
20920 Fascia lata graft; by stripper
29022 Fascia lata graft; by incision and area exposure, complex or sheet
20926 Tissue grafts, other (e.g., paratenon, fat, dermis)
53500 Urethrolysis, transvaginal, secondary, open, including cystourethroscopy (e.g., postsurgical obstruction, scarring)
57287 Removal or revision of sling for stress incontinence (e.g., fascia or synthetic)
57288 Sling operation for stress incontinence (e.g., fascia or synthetic)
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